Preview Mode Links will not work in preview mode

This Week in Cardiology

Dec 16, 2022

BP control over the long term, omecamtiv mecarbil, incentives and Goodhart’s law, and open science are the topics John Mandrola, MD, covers in this week’s podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit:

I. Long-Term BP Control

- Final SPRINT Data Confirm Lower BP Is Better

- Longer-Term All-Cause and Cardiovascular Mortality With Intensive Blood Pressure Control

- Let's Not SPRINT to Judgment About New Blood Pressure Goals

- Should We SPRINT Toward New Blood Pressure Goals or Let the Dust Settle?

II. Omecamtiv Mecarbil

- FDA Panel Votes No on Omecamtiv Mecarbil for Heart Failure

- Omecamtiv Mecarbil Fails to Improve Exercise Capacity in HFrEF

- Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure

- Effect of Omecamtiv Mecarbil on Exercise Capacity in Chronic Heart Failure With Reduced Ejection Fraction

- Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trial

III. Measuring Quality of Care

- MIPS Quality Scores Don't Reflect Quality of Care: Study

- Association Between Individual Primary Care Physician Merit-based Incentive Payment System Score and Measures of Process and Patient Outcomes

- Pay for Performance When Slogans Overtake Science in Health Policy

- Goodhart's law

IV. Open Science

- Radial Artery Outlasts SVG as Second CABG Conduit, Cuts 5-Year Clinical Risk

- Many Analysts, One Data Set: Making Transparent How Variations in Analytic Choices Affect Results

- Radial artery versus saphenous vein versus right internal thoracic artery for coronary artery bypass grafting

- Do all roads lead to Rome? Critical reassessment of the individual patient meta-analysis on bypass grafts by Gaudino et al.

- Editorial: Radial artery versus saphenous vein versus right internal thoracic artery for coronary artery bypass grafting: Different conduits or different trials?


- Mandrola’s Top 10 Cardiology Stories of 2022

You may also like:

Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine

The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.

Questions or feedback, please contact